Subclinical impairment of left ventricular myocardium function in type 2 diabetes mellitus patients with or without hypertension

doi:10.4239/wjd.v15.i6.1272

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (151)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

101

Figures (1-1)

Tables (1-4)

Sum=145

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Jun 15, 2024 (publication date) through Jun 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Jun 15, 2024; 15(6): 1272-1279
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1272

Table 1 Clinical parameters of patients with healthy subjects, type 2 diabetes mellitus patients and type 2 diabetes mellitus patients with hypertension

Clinical parameters	Healthy subjects (n = 101)	T2DM (n = 97)	T2DM + HP (n = 70)	P value
Age, yr	48.06 ± 9.90	49.04 ± 12.80	52.00 ± 11.50	0.068
Male, n (%)	48 (48)	61 (63)	39 (56)	0.094
Hight, cm	165.10 ± 7.50	166.87 ± 9.25	164.66 ± 7.53	0.199
Wight, kg	64.14 ± 10.58	72.50 ± 15.34¹	72.23 ± 13.80¹	< 0.001
BMI, kg/m²	23.44 ± 2.84	25.85 ± 3.90¹	26.51 ± 4.02¹	< 0.001
BSA, m²	1.68 ± 0.17	1.79 ± 0.24¹	1.78 ± 0.21¹	< 0.001
SBP, mmHg	123.26 ± 10.82	127.65 ± 14.70¹	137.07 ± 17.34¹^,²	< 0.001
DBP, mmHg	77.85 ± 7.65	79.25 ± 10.59	86.64 ± 10.20¹^,²	< 0.001
HR, bpm	69.85 ± 9.76	75.22 ± 9.60¹	79.10 ± 12.72¹^,²	<0.001
FPG, mmol/L	4.95 (4.59, 5.25)	10.53 (7.87, 14.07)¹	8.91 (7.57, 10.97)¹	< 0.001
HbA1c, %	5.45 ± 0.38	9.73 ± 2.27¹	8.85 ± 2.49¹^,²	< 0.001
TC, mmol/L	4.54 ± 0.85	4.37 ± 0.90	4.70 ± 1.14	0.102
TG, mmol/L	1.21 (0.88,1.78)	1.53 (0.97, 2.15)¹	2.00 (1.38, 2.83)¹^,²	< 0.001
HDL-C, mmol/L	1.27 ± 0.30	1.09 ± 0.29¹	1.04 ± 0.28¹	< 0.001
LDL-C, mmol/L	2.68 ± 0.70	2.65 ± 0.79	2.81 ± 0.99	0.556
LPA, g/L	0.17 (0.11, 0.28)	0.14 (0.06, 0.24)	0.14 (0.08, 0.25)	0.231
BUN, mmol/L	4.75 (3.60, 5.70)	5.50 (4.60, 6.30)¹	5.50 (4.50, 7.40)¹	0.001
SCR, μmol/L	61.00 (55.00, 76.00)	59.00 (49.30, 71.10)	64.00 (54.00, 87.00)²	0.030
Medication, n (%)
ACEI/ARB	-	-	32 (46)
Calcium channel blocker	-	-	37 (53)
β-blocker	-	-	4 (6)
SGLT-2 inhibitor	-	18 (19)	28 (40)
Metformin	-	59 (61)	38 (54)
Insulin	-	55 (57)	35 (50)

¹Significantly different (P < 0.05) between type 2 diabetes mellitus (T2DM) or T2DM + hypertension (HP) patients and healthy subjects.

²Significantly different (P < 0.05) between T2DM + HP patients and T2DM patients.

BMI: Body mass index; BSA: Body surface area; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HR: Heart rate; FPG: Fasting plasma glucose; HbA1c: Glycated haemoglobin; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein; LDL-C: Low-density lipoprotein; BUN: Blood urea nitrogen; SCR: Serum creatinine.

Table 2 Echocardiographic parameters among healthy subjects, type 2 diabetes mellitus patients, and type 2 diabetes mellitus + hypertension patients

Echocardiographic parameters	Healthy subjects (n = 101)	T2DM (n = 97)	T2DM + HP (n = 70)	P value
LAd, mm	34.00 ± 2.97	35.03 ± 3.04¹	36.69 ± 3.91¹^,²	< 0.001
LAV index, mL/m²	29.17 ± 7.19	32.20 ± 6.80¹	30.92 ± 8.10	0.016
IVSd, mm	9.21 ± 0.79	9.01 ± 0.98	9.71 ± 0.95¹^,²	< 0.001
LVPWd, mm	9.01 ± 0.80	8.81 ± 0.93	9.53 ± 1.00¹^,²	< 0.001
LVDd, mm	46.39 ± 2.95	45.85 ± 3.49	46.89 ± 3.40	0.124
LVEDV, mL	76.61 ± 15.17	69.57 ± 20.54¹	76.77 ± 22.26²	0.018
LVESV, mL	27.19 ± 6.65	25.01 ± 8.14	27.93 ± 8.76²	0.037
LVEF, %	64.56 ± 3.74	64.35 ± 2.89	63.54 ± 2.71	0.080
MAPSE, mm	14.47 ± 1.44	14.23 ± 1.75	13.42 ± 2.07¹^,²	0.002
E, m/s	0.83 ± 0.13	0.78 ± 0.14¹	0.78 ± 0.16¹	0.008
A, m/s	0.68 ± 0.16	0.69 ± 0.15	0.82 ± 0.18¹^,²	< 0.001
E/A	1.27 ± 0.29	1.16 ± 0.29¹	1.00 ± 0.36¹^,²	< 0.001
e’, m/s	0.11 ± 0.02	0.10 ± 0.02	0.10 ± 0.11	0.117
E/e’	7.62 ± 1.54	8.30 ± 1.63¹	9.00 ± 2.47¹^,²	< 0.001

¹Significantly different (P < 0.05) between type 2 diabetes mellitus (T2DM) or T2DM + hypertension (HP) patients and healthy subjects.

²Significantly different (P < 0.05) between T2DM + HP patients and T2DM patients.

LAd: Left atrial diameter; LAV index: Left atrial volume index; IVSd: Interventricular septal wall thickness in the end-diastolic period; LVPWd: Left ventricular posterior wall thickness in the end-diastolic period; LVDd: Left ventricular diameter in the end-diastolic period; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; MAPSE: Mitral annular plane systolic excursion; E: Peak velocity during early diastole of anterior mitral leaflet; A: Peak velocity during late diastole of anterior mitral leaflet; e’: Peak early diastolic annular velocities using TDI by averaging the values at the septum and lateral positions.

Table 3 Layer-specific global longitudinal strain and peak strain dispersion among healthy subjects, type 2 diabetes mellitus patients, and type 2 diabetes mellitus + hypertension patients

	Healthy subjects (n = 101)	T2DM (n = 97)	T2DM + HP (n = 70)	P₁ value	P_trend value
GLSepi, %	-18.66 ± 1.58	-17.33 ± 1.93¹	-16.74 ± 1.93¹^,²	< 0.001	< 0.001
GLSmid, %	-21.58 ± 1.84³	-19.87 ± 2.21¹^,³	-19.28 ± 2.16¹^,³	< 0.001	< 0.001
GLSendo, %	-25.03 ± 2.24³^,⁴	-22.97 ± 2.56¹^,³^,⁴	-22.48 ± 2.50¹^,³^,⁴	< 0.001	< 0.001
PSD, msec	28.79 ± 7.25	34.92 ± 11.19¹	39.23 ± 11.47¹^,²	< 0.001	< 0.001
P2 value	< 0.001	< 0.001	< 0.001

¹Significantly different (P < 0.05) between type 2 diabetes mellitus (T2DM) or T2DM + hypertension (HP) patients and healthy subjects.

²Significantly different (P < 0.05) between T2DM + HP patients and T2DM patients.

³Significant difference (P < 0.05) of GLSmid and GLSendo vs GLSepi in healthy subjects, T2DM patients and T2DM + HP patients.

⁴Significant difference (P < 0.05) of GLSendo vs GLSmid in healthy subjects, T2DM patients and T2DM + HP patients.

P1: Difference between healthy subjects and T2DM and T2DM + HP patients; P2: Difference between GLSepi, GLSmid and GLSendo in healthy subjects, T2DM patients or T2DM + HP patients. GLS: Global longitudinal strain; GLSEpi: Global longitudinal strain of the epimyocardium; GLSMid: Global longitudinal strain of the middle myocardium; GLSEndo: Global longitudinal strain of the endocardium; PSD: Peak strain dispersion.

Table 4 Intraclass correlation coefficients for intra- and interobserver variability for layer-specific global longitudinal strain and peak strain dispersion

Variable	Interobserver variability		Intraobserver variability
Variable	ICC	95%CI	ICC	95%CI
GLSendo	0.959	0.896-0.984	0.964	0.909-0.986
GLSmid	0.965	0.911-0.986	0.973	0.933-0.989
GLSepi	0.959	0.898-0.984	0.975	0.936-0.990
PSD	0.955	0.887-0.982	0.976	0.939-0.990

GLS: Global longitudinal strain; PSD: Peak strain dispersion; ICC: Intraclass correlation coefficient; 95%CI: 95% confidence interval.

Citation: Chen ZG, Li GA, Huang J, Fan L. Subclinical impairment of left ventricular myocardium function in type 2 diabetes mellitus patients with or without hypertension. World J Diabetes 2024; 15(6): 1272-1279
URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1272.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1272